Eikon Therapeutics, Inc. SEC filings EIKN
Eikon Therapeutics, Inc. has 67 filings in SEC EDGAR's recent list, going back to May 13, 2021. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 7, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 2, 2026 | — |
| 4 | Insider transaction | Sep 8, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 14, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 6, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Aug 3, 2026 | Jul 31, 2026 |
| 3 | Initial insider ownership | Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 10, 2026 | Jun 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 1, 2026 | May 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 13, 2026 | — |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 11, 2026 | May 11, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 6, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 29, 2026 | — |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 18, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Feb 12, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 11, 2026 | — |
| 4 | Insider transaction | Feb 10, 2026 | Feb 6, 2026 |
| 4 | Insider transaction | Feb 9, 2026 | Feb 6, 2026 |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| S-8 | Employee stock plan registration | Feb 6, 2026 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 6, 2026 | Feb 6, 2026 |
| 424B4 | Prospectus | Feb 5, 2026 | — |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 4, 2026 | Feb 4, 2026 |
| S-1MEF | Filing | Feb 4, 2026 | — |
| CERT | Filing | Feb 4, 2026 | — |
| EFFECT | Filing | Jan 30, 2026 | — |
| 8-A12B | Filing | Jan 28, 2026 | — |
| S-1/A | Amended registration statement | Jan 28, 2026 | — |
| S-1 | Registration statement | Jan 9, 2026 | — |
| DRS/A | Filing | Dec 12, 2025 | — |
| DRS/A | Filing | Sep 26, 2025 | — |
| DRS/A | Filing | Jul 1, 2025 | — |
| DRS | Filing | May 9, 2025 | — |
| D | Filing | Feb 28, 2025 | — |
| D | Filing | Jun 1, 2023 | — |
| D | Filing | Jan 6, 2022 | — |
| D | Filing | May 13, 2021 | — |
Showing 67 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EIKN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Millbrae, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1861123
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.